Anti-LAG-3 抗体 [EPR4392(2)] - C-terminal (ab180187)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4392(2)] to LAG-3 - C-terminal
- Suitable for: IHC-P
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-LAG-3 antibody [EPR4392(2)] - C-terminal
LAG-3 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR4392(2)] to LAG-3 - C-terminal -
由来種
Rabbit -
アプリケーション
適用あり: IHC-Pmore details
適用なし: ICC/IF,IP or WB -
種交差性
交差種: Human -
免疫原
Synthetic peptide within Human LAG-3 aa 450 to the C-terminus (Cysteine residue). The exact sequence is proprietary.
Database link: P18627 -
ポジティブ・コントロール
- Human Hodgkins lymphoma and Human tonsil tissues
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR4392(2) -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab180187の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-P | (2) |
1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
特記事項 |
---|
IHC-P
1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
ターゲット情報
-
機能
Involved in lymphocyte activation. Binds to HLA class-II antigens. -
組織特異性
On cell surface of activated NK and T-lymphocytes. -
配列類似性
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 3902 Human
- Omim: 153337 Human
- SwissProt: P18627 Human
- Unigene: 409523 Human
-
別名
- CD223 antibody
- CD223 antigen antibody
- FDC protein antibody
see all
画像
-
Immunohistochemical analysis of paraffin embedded Human tonsil tissue labeling LAG-3 with ab180187 at 1/1000.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin embedded Human Hodgkins lymphoma tissue labeling LAG-3 with ab180187 at 1/1000.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (12)
ab180187 は 12 報の論文で使用されています。
- Luo F et al. Correction to: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. Cancer Cell Int 22:46 (2022). PubMed: 35093085
- Machiraju D et al. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. Oncoimmunology 10:1926762 (2021). ELISA, IHC-P ; Human . PubMed: 34104542
- Cen S et al. BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. Front Cell Dev Biol 9:705060 (2021). PubMed: 34381786
- Peng QQ et al. Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer. Neoplasma 68:742-750 (2021). PubMed: 33847134
- Sorrentino C et al. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Front Immunol 12:778329 (2021). PubMed: 34975867